Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 0.897 AUD -6.56% Market Closed
Market Cap: AU$243.2m

Net Margin

-92.8%
Current
Improving
by 37.1%
vs 3-y average of -129.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-92.8%
=
Net Income
AU$-8.6m
/
Revenue
AU$9.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-92.8%
=
Net Income
AU$-8.6m
/
Revenue
AU$9.2m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Orthocell Ltd
ASX:OCC
243.2m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
43rd
Based on 4 004 companies
43rd percentile
-92.8%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Orthocell Ltd
Glance View

Market Cap
243.2m AUD
Industry
Biotechnology

Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.

OCC Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-92.8%
=
Net Income
AU$-8.6m
/
Revenue
AU$9.2m
What is Orthocell Ltd's current Net Margin?

The current Net Margin for Orthocell Ltd is -92.8%, which is above its 3-year median of -129.9%.

How has Net Margin changed over time?

Over the last 3 years, Orthocell Ltd’s Net Margin has increased from -563.6% to -92.8%. During this period, it reached a low of -563.6% on Jun 30, 2022 and a high of -41.4% on Dec 31, 2024.

Back to Top